Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 133

1.

Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.

Zhang Q, Xia Z, Mitten MJ, Lasko LM, Klinghofer V, Bouska J, Johnson EF, Penning TD, Luo Y, Giranda VL, Shoemaker AR, Stewart KD, Djuric SW, Vasudevan A.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7615-22. doi: 10.1016/j.bmcl.2012.10.009. Epub 2012 Oct 11.

PMID:
23103095
[PubMed - indexed for MEDLINE]
2.

Identification of novel, potent and selective inhibitors of Polo-like kinase 1.

Chen S, Bartkovitz D, Cai J, Chen Y, Chen Z, Chu XJ, Le K, Le NT, Luk KC, Mischke S, Naderi-Oboodi G, Boylan JF, Nevins T, Qing W, Chen Y, Wovkulich PM.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1247-50. doi: 10.1016/j.bmcl.2011.11.052. Epub 2011 Dec 1.

PMID:
22172702
[PubMed - indexed for MEDLINE]
3.

Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.

Sato Y, Onozaki Y, Sugimoto T, Kurihara H, Kamijo K, Kadowaki C, Tsujino T, Watanabe A, Otsuki S, Mitsuya M, Iida M, Haze K, Machida T, Nakatsuru Y, Komatani H, Kotani H, Iwasawa Y.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4673-8. doi: 10.1016/j.bmcl.2009.06.084. Epub 2009 Jun 25.

PMID:
19589677
[PubMed - indexed for MEDLINE]
4.

Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.

Lu S, Sun SL, Liu HC, Chen YD, Yuan HL, Gao YP, Yang P, Lu T.

Chem Biol Drug Des. 2012 Aug;80(2):328-39. doi: 10.1111/j.1747-0285.2012.01412.x. Epub 2012 Jun 8.

PMID:
22583481
[PubMed - indexed for MEDLINE]
5.

TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.

Hikichi Y, Honda K, Hikami K, Miyashita H, Kaieda I, Murai S, Uchiyama N, Hasegawa M, Kawamoto T, Sato T, Ichikawa T, Cao S, Nie Z, Zhang L, Yang J, Kuida K, Kupperman E.

Mol Cancer Ther. 2012 Mar;11(3):700-9. doi: 10.1158/1535-7163.MCT-11-0762. Epub 2011 Dec 21.

PMID:
22188812
[PubMed - indexed for MEDLINE]
Free Article
6.

Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.

Beria I, Ballinari D, Bertrand JA, Borghi D, Bossi RT, Brasca MG, Cappella P, Caruso M, Ceccarelli W, Ciavolella A, Cristiani C, Croci V, De Ponti A, Fachin G, Ferguson RD, Lansen J, Moll JK, Pesenti E, Posteri H, Perego R, Rocchetti M, Storici P, Volpi D, Valsasina B.

J Med Chem. 2010 May 13;53(9):3532-51. doi: 10.1021/jm901713n.

PMID:
20397705
[PubMed - indexed for MEDLINE]
7.

NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.

Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B.

Bioorg Med Chem Lett. 2011 May 15;21(10):2969-74. doi: 10.1016/j.bmcl.2011.03.054. Epub 2011 Mar 21.

PMID:
21470862
[PubMed - indexed for MEDLINE]
8.

A novel anti-tumor inhibitor identified by virtual screen with PLK1 structure and zebrafish assay.

Lu J, Xin S, Meng H, Veldman M, Schoenfeld D, Che C, Yan R, Zhong H, Li S, Lin S.

PLoS One. 2013 Apr 26;8(4):e53317. doi: 10.1371/journal.pone.0053317. Print 2013.

PMID:
23658603
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1.

Richter S, Neundorf I, Loebner K, Gräber M, Berg T, Bergmann R, Steinbach J, Pietzsch J, Wuest F.

Bioorg Med Chem Lett. 2011 Aug 15;21(16):4686-9. doi: 10.1016/j.bmcl.2011.06.103. Epub 2011 Jun 30.

PMID:
21778054
[PubMed - indexed for MEDLINE]
10.

4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors.

Beria I, Valsasina B, Brasca MG, Ceccarelli W, Colombo M, Cribioli S, Fachin G, Ferguson RD, Fiorentini F, Gianellini LM, Giorgini ML, Moll JK, Posteri H, Pezzetta D, Roletto F, Sola F, Tesei D, Caruso M.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6489-94. doi: 10.1016/j.bmcl.2010.09.060. Epub 2010 Sep 17.

PMID:
20932759
[PubMed - indexed for MEDLINE]
11.

Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.

Cheung AK, Ip JC, Lung HL, Wu JZ, Tsao SW, Lung ML.

Mol Cancer Ther. 2013 Aug;12(8):1393-401. doi: 10.1158/1535-7163.MCT-12-1219. Epub 2013 May 17.

PMID:
23686835
[PubMed - indexed for MEDLINE]
Free Article
12.

Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.

Rheault TR, Donaldson KH, Badiang-Alberti JG, Davis-Ward RG, Andrews CW, Bambal R, Jackson JR, Cheung M.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4587-92. doi: 10.1016/j.bmcl.2010.06.009. Epub 2010 Jun 8.

PMID:
20594842
[PubMed - indexed for MEDLINE]
13.

Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).

Uckun FM, Dibirdik I, Qazi S, Vassilev A, Ma H, Mao C, Benyumov A, Emami KH.

Bioorg Med Chem. 2007 Jan 15;15(2):800-14. Epub 2006 Oct 26.

PMID:
17098432
[PubMed - indexed for MEDLINE]
14.

Imidazo[5,1-f][1,2,4]triazin-2-amines as novel inhibitors of polo-like kinase 1.

Cheung M, Kuntz KW, Pobanz M, Salovich JM, Wilson BJ, Andrews CW 3rd, Shewchuk LM, Epperly AH, Hassler DF, Leesnitzer MA, Smith JL, Smith GK, Lansing TJ, Mook RA Jr.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6214-7. doi: 10.1016/j.bmcl.2008.09.100. Epub 2008 Oct 2.

PMID:
18929484
[PubMed - indexed for MEDLINE]
15.

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2014 Jan;61(1):158-64. doi: 10.1002/pbc.24616. Epub 2013 Aug 19.

PMID:
23956067
[PubMed - indexed for MEDLINE]
16.

Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.

Mita Y, Noguchi-Yachide T, Ishikawa M, Hashimoto Y.

Bioorg Med Chem. 2013 Feb 1;21(3):608-17. doi: 10.1016/j.bmc.2012.11.054. Epub 2012 Dec 11.

PMID:
23276450
[PubMed - indexed for MEDLINE]
17.

NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.

Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, Cappella P, Caruso M, Casolaro A, Ciavolella A, Cucchi U, De Ponti A, Felder E, Fiorentini F, Galvani A, Gianellini LM, Giorgini ML, Isacchi A, Lansen J, Pesenti E, Rizzi S, Rocchetti M, Sola F, Moll J.

Mol Cancer Ther. 2012 Apr;11(4):1006-16. doi: 10.1158/1535-7163.MCT-11-0765. Epub 2012 Feb 7.

PMID:
22319201
[PubMed - indexed for MEDLINE]
Free Article
18.

SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.

Forsyth T, Kearney PC, Kim BG, Johnson HW, Aay N, Arcalas A, Brown DS, Chan V, Chen J, Du H, Epshteyn S, Galan AA, Huynh TP, Ibrahim MA, Kane B, Koltun ES, Mann G, Meyr LE, Lee MS, Lewis GL, Noguchi RT, Pack M, Ridgway BH, Shi X, Takeuchi CS, Zu P, Leahy JW, Nuss JM, Aoyama R, Engst S, Gendreau SB, Kassees R, Li J, Lin SH, Martini JF, Stout T, Tong P, Woolfrey J, Zhang W, Yu P.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7653-8. doi: 10.1016/j.bmcl.2012.10.007. Epub 2012 Oct 16.

PMID:
23127890
[PubMed - indexed for MEDLINE]
19.

Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.

Lan R, Lin G, Yin F, Xu J, Zhang X, Wang J, Wang Y, Gong J, Ding YH, Yang Z, Lu F, Zhang H.

Lab Invest. 2012 Oct;92(10):1503-14. doi: 10.1038/labinvest.2012.114. Epub 2012 Aug 13.

PMID:
22890557
[PubMed - indexed for MEDLINE]
Free Article
20.

A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.

Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T.

Chembiochem. 2009 May 4;10(7):1145-8. doi: 10.1002/cbic.200900059.

PMID:
19350612
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk